


Appl. No. : 10/673,036
Filed : September 25, 2003

AMENDMENTS TO THE CLAIMS

1-9 (Canceled)

10. (Currently amended) A substantially purified compound having the following structure:



or its acid-addition salts or its pro-drug esters.

11. (Currently amended) A method of treating an individual with cancer, comprising: administering to the individual a compound of Claim 10, its acid-addition salts or its pro-drug esters, wherein the cancer is selected from the group consisting of an adenocarcinoma colon cancer, a prostate cancer, a T-cell leukemia, and a melanoma cancer.

12. (Currently amended) A method of treating cancer comprising the step of contacting a cancer cell with a compound of Claim 10, wherein the cancer is selected from the group consisting of an adenocarcinoma colon cancer, a prostate cancer, a T-cell leukemia, and a melanoma cancer.

13. (Currently amended) The method of Claim 12, wherein the cancer is an adenocarcinoma colon cancer.

14. (Original) The method of Claim 12, wherein the cancer is a prostate cancer.

15. (Currently amended) The method of Claim 12, wherein the cancer is a T-cell leukemia.

16. (Original) The method of Claim 12, wherein the cancer is a melanoma cancer.

17. (Canceled).

18. (Currently amended) The method of Claim 11, wherein the cancer is an adenocarcinoma colon cancer.

19. (Previously presented) The method of Claim 11, wherein the cancer is a prostate cancer.

Appl. No. : 10/673,036
Filed : September 25, 2003

20. (Currently amended) The method of Claim 11, wherein the cancer is a T-cell leukemia.

21. (Previously presented) The method of Claim 11, wherein the cancer is a melanoma cancer.

22. (Previously presented) The method of Claim 11, wherein the compound is administered with a pharmaceutically acceptable carrier, diluent, or excipient.

23. (Currently amended) A method of treating an individual with cancer, comprising administering to the individual a composition comprising the compound of Claim 10, an acid-addition salt thereof, or a pro-drug ester therof, wherein the cancer is selected from the group consisting of an adenocarcinoma colon cancer, a prostate cancer, a T-cell leukemia, and a melanoma cancer.

24. (Previously presented) The method of Claim 23, wherein the composition is administered with a pharmaceutically acceptable carrier, diluent, or excipient.

25. (Currently amended) The method of Claim 23, wherein the cancer is an adenocarcinoma colon cancer.

26. (Previously presented) The method of Claim 23, wherein the cancer is a prostate cancer.

27. (Currently amended) The method of Claim 23, wherein the cancer is a T-cell leukemia.

28. (Previously presented) The method of Claim 23, wherein the cancer is a melanoma cancer.